Genprex Identifies Key Biomarkers for Lung Cancer Gene Therapy Response
Event summary
- Genprex presented clinical data at ASCO 2026 showing Trop-2 H-scores above 100 and PTEN H-scores below 100 correlated with longer progression-free survival in NSCLC patients treated with Reqorsa®.
- The findings were derived from 18 patients across three clinical trials (Acclaim-1, Acclaim-2, Acclaim-3).
- High Trop-2 expression will be further investigated as a potential biomarker for Reqorsa®.
- The Acclaim-1 and Acclaim-3 trials have received FDA Fast Track Designation, and Acclaim-3 has Orphan Drug Designation for SCLC.
The big picture
Genprex's findings at ASCO 2026 highlight the growing importance of biomarker-driven approaches in oncology, particularly for gene therapies. The ability to predict patient response could enhance Reqorsa®'s competitive positioning in the lung cancer space, where precision medicine is increasingly becoming the standard of care. The FDA's Fast Track and Orphan Drug Designations further underscore the strategic value of Genprex's pipeline in addressing high-unmet medical needs.
What we're watching
- Biomarker Validation
- Whether Trop-2 and PTEN biomarkers can be reliably used for patient selection in future Reqorsa® trials.
- Clinical Development
- The pace at which Genprex advances its lung cancer programs, particularly with the Fast Track Designation.
- Regulatory Strategy
- How the FDA's Orphan Drug Designation for SCLC could accelerate Reqorsa®'s path to market.
Related topics